Phenobarbital

Introduction Overview

Generic Name

phenobarbital

Brand Name

Solfoton, Luminal, Sezaby

Dosage Form

oral elixir (20 mg/5 mL), oral tablet (100 mg; 15 mg; 16.2 mg; 30 mg; 32.4 mg; 60 mg; 64.8 mg; 97.2 mg)

Drug Class

Barbiturate anticonvulsants, Barbiturates

Pharmacokinetics

Absorption:
Phenobarbital is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations typically occur within 1 to 4 hours after ingestion. The oral elixir and tablet formulations provide reliable and predictable absorption, making oral administration a convenient and effective route for chronic treatment. The relative bioavailability is high, with oral doses closely correlating with plasma levels. Food may delay absorption slightly but does not significantly affect overall bioavailability.

Distribution:
Phenobarbital exhibits moderate plasma protein binding, approximately 40-60%, primarily to albumin. It distributes extensively into body tissues, including the brain, where it exerts its anticonvulsant effects. The apparent volume of distribution ranges from 0.5 to 0.9 L/kg. Phenobarbital crosses the placenta and is secreted in breast milk, posing potential considerations for pregnant and nursing patients. Due to its lipophilicity and moderate protein binding, phenobarbital distributes well but can accumulate in fatty tissues during prolonged therapy.

Metabolism:
Phenobarbital undergoes partial hepatic metabolism, primarily via hydroxylation pathways mediated by cytochrome P450 enzymes, particularly CYP2C9 and CYP2C19 isoforms. Approximately 25% is metabolized hepatically into inactive metabolites, while the remaining majority is excreted unchanged. Phenobarbital acts as an inducer of hepatic microsomal enzymes, which can increase its own metabolism over time (auto-induction) and affect concurrent medications.

Elimination:
Phenobarbital is predominantly eliminated by renal excretion, primarily as unchanged drug (about 70-75%), with the remainder as metabolites. The elimination half-life is variable, typically ranging from 53 to 118 hours but may be shorter in children (around 40-50 hours) or longer in elderly patients or those with hepatic impairment. Renal function significantly influences clearance, and dose adjustments may be necessary in renal dysfunction. The long half-life supports once-daily or twice-daily dosing regimens for seizure control.

Dosage Forms

Available Dosage Forms:
- Oral elixir: 20 mg/5 mL
- Oral tablet: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg

Dosages for Adults and Adolescents:
Phenobarbital dosing varies depending on the indication (e.g., seizure type, sedation). Typical adult doses for seizure control start at 60 to 200 mg per day, divided or given once daily, with maximum doses up to 400 mg/day depending on clinical response and tolerance. Dosage should be individualized based on patient response and serum drug levels. For sedation, short-term dosing is used at lower doses.

Specific Patient Populations:
- Pediatric Dosing: Dose usually based on weight (e.g., initial 3 to 5 mg/kg/day, can be adjusted), with careful titration to effect and monitoring of serum levels.
- Geriatric Patients: May require dose reduction due to altered pharmacokinetics and increased sensitivity to sedative effects.
- Hepatic or Renal Impairment: Dose adjustments recommended due to decreased metabolism and/or clearance.
- Pregnancy: Close monitoring is essential; phenobarbital crosses placenta and may require dose adjustment.
- Breastfeeding: Caution advised; phenobarbital passes into breast milk and may cause sedation in the infant.

Clinical guidelines emphasize maintaining therapeutic serum phenobarbital concentrations usually between 15 and 40 mcg/mL for seizure control, with dosage adjustments guided by clinical response and serum level monitoring.

Mechanism Of Action

Phenobarbital exerts its primary pharmacological action through enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission in the central nervous system. By binding to the barbiturate site on the GABA_A receptor complex, phenobarbital prolongs the duration of chloride ion channel opening induced by GABA binding. This leads to an increased influx of chloride ions into neurons, hyperpolarizing the neuronal membrane and reducing neuronal excitability.

At the cellular level, phenobarbital stabilizes the inactive state of voltage-gated sodium channels and inhibits excitatory neurotransmission by depressing glutamate responses. This dual action results in a generalized depressant effect on synaptic transmission, which manifests clinically as anticonvulsant, sedative, and hypnotic properties. Phenobarbital’s modulation of synaptic activity reduces the spread of seizure activity and raises the seizure threshold.

Unlike benzodiazepines that increase the frequency of GABA_A receptor channel opening, phenobarbital prolongs the duration of these openings, leading to a more sustained inhibitory effect. This distinct mechanism offers a therapeutic advantage in controlling generalized tonic-clonic and partial seizures. However, phenobarbital's broad CNS depressant effects may account for sedative and adverse neuropsychiatric side effects.

Extensive clinical studies have validated phenobarbital's efficacy in seizure prevention and treatment, especially in resource-limited settings due to its low cost and well-characterized profile. Research continues to explore molecular interactions and potential neuroprotective roles, but the primary clinical applications revolve around its GABAergic enhancement and neuronal stabilizing effects.

Pharmacological Actions

Enhances GABA_A receptor-mediated inhibitory neurotransmission by prolonging chloride ion channel opening.
Stabilizes neuronal membranes by increasing the threshold for electrical stimulation.
Inhibits excitatory neurotransmitter glutamate activity, reducing neuronal firing.
Produces anticonvulsant effects primarily by suppressing seizure spread and raising seizure threshold.
Exerts sedative and hypnotic effects through CNS depression.
Acts as a central nervous system depressant with anxiolytic properties at therapeutic doses.
Induces hepatic microsomal enzymes leading to increased metabolism of various drugs (auto-induction).
Exhibits muscle relaxant properties contributing to its sedative profile.
Displays synergy with other anticonvulsants, useful in polytherapy for refractory seizures.
Can produce tolerance and physical dependence with prolonged use.

Therapeutic Or Clinical Uses

Management and prevention of generalized tonic-clonic seizures.
Control of partial seizures with complex symptomatology.
Short-term sedation to relieve anxiety and induce relaxation.
Treatment of neonatal seizures and hyperbilirubinemia in newborns (off-label use).
Status epilepticus adjunct therapy when first-line agents are ineffective or unavailable.
Prophylaxis for febrile seizures in at-risk pediatric populations (selected cases).
Adjunct in the management of certain types of nerve pain (off-label).
Used in some cases during anesthesia premedication for sedation.
Management of certain alcohol withdrawal symptoms due to CNS depressant effects.

Side Or Adverse Effects

Drowsiness and sedation, which may persist into the next day ('hangover' effect).
Dizziness, impaired coordination, and ataxia.
Depressed mood, confusion, and cognitive impairment, particularly in elderly or debilitated patients.
Paradoxical excitement, restlessness, or irritability, especially in children and older adults.
Respiratory depression at high doses or when combined with other CNS depressants.
Severe allergic reactions including hives, swelling of face, lips, tongue or throat, and difficulty breathing.
Hematologic abnormalities such as red blood cell disorders leading to pale skin, weakness, and shortness of breath.
Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis characterized by rash, blistering, and peeling.
Physical dependence and withdrawal symptoms upon abrupt discontinuation after prolonged use.
Cognitive blunting and reduced mental alertness with chronic therapy.
Potential hepatic toxicity or exacerbation of liver disease.
Gastrointestinal disturbances including nausea and constipation.
Respiratory complications in patients with asthma or COPD.
Potential for fetal harm when used during pregnancy; risk of neonatal withdrawal or congenital malformations.
Risk of overdose leading to coma, respiratory arrest, and death.

Precautions

Use with caution in patients with liver dysfunction due to altered metabolism and clearance.
Avoid in patients with severe asthma or chronic obstructive pulmonary disease (COPD) due to risk of respiratory depression.
Screen for a personal or family history of porphyria, which can be exacerbated by phenobarbital.
Monitor for signs of drug dependence, and avoid abrupt discontinuation to prevent withdrawal seizures.
Use cautiously in elderly patients and debilitated individuals due to increased sensitivity to CNS effects.
Adjust doses in renal impairment to prevent drug accumulation and toxicity.
Advise patients on potential for sedation and impaired mental or motor performance, and caution against driving or operating machinery.
Assess pregnancy status prior to initiation and monitor closely during pregnancy due to teratogenic risk.
Advise on use of additional or alternative contraception methods as phenobarbital can decrease effectiveness of hormonal contraceptives.
Patients with a history of drug addiction should be carefully evaluated before prescribing phenobarbital.
Avoid concurrent use of other CNS depressants without close medical supervision.
Regularly monitor serum phenobarbital concentrations to optimize therapy and minimize toxicity.
Caution with co-administration of blood thinners like warfarin; monitor INR closely.
Be vigilant for signs of severe skin reactions; discontinue drug immediately if symptoms develop.
Educate patients and caregivers about signs of allergic reactions and need for emergency medical care.

Warnings

Contraindicated in patients with known hypersensitivity to phenobarbital or other barbiturates.
Not to be used in individuals with severe liver disease due to risk of drug accumulation and hepatotoxicity.
Avoid use in patients with severe respiratory insufficiency, including severe asthma or COPD, due to risk of respiratory depression.
Contraindicated in patients with known porphyria, as phenobarbital can precipitate an acute attack.
Use is contraindicated in patients with a history of addiction to barbiturates or drugs with similar CNS depressant effects.
Risk of severe and potentially fatal overdose; use with extreme caution and adhere strictly to prescribed doses.
May cause severe dermatological reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Black box warning for potential for physical and psychological dependence, abuse, and addiction.
Pregnancy Category D: fetal risk; seizures should be controlled during pregnancy but fetal exposure carries known risks.
Long-term use requires monitoring for tolerance, physical dependence, and withdrawal phenomena.
Discontinue gradually under medical supervision to avoid withdrawal seizures and status epilepticus.
Use with other CNS depressants (e.g., opioids, benzodiazepines, alcohol) can potentiate respiratory depression and sedation.
Severe respiratory depression and coma have been reported in overdose situations.
Sudden cessation can lead to severe withdrawal symptoms including seizures and delirium.
Patients should be closely monitored for signs of overdose and toxicity.

Contraindication

Hypersensitivity to phenobarbital or other barbiturates.
Severe liver disease, including hepatic failure.
Severe respiratory depression or severe asthma and chronic obstructive pulmonary disease (COPD).
Personal or family history of porphyria (an inherited disorder affecting heme biosynthesis).
History of addiction to phenobarbital or other barbiturates.
Use in patients with respiratory conditions predisposing to respiratory failure.
Concomitant use with other agents contraindicated with barbiturates (e.g., certain CNS depressants without close monitoring).
Comatose patients or those with pre-existing severe central nervous system depression.
Known severe skin reactions or prior Stevens-Johnson syndrome linked to barbiturates.
Relative contraindications include certain psychiatric disorders due to risk of exacerbation.

Drug Interactions

Induces hepatic cytochrome P450 enzymes (notably CYP2C and CYP3A), reducing plasma levels and efficacy of many drugs including warfarin, oral contraceptives, corticosteroids, and certain antiepileptics.
Concurrent use with other CNS depressants such as benzodiazepines, opioids, and alcohol increases risk of profound sedation and respiratory depression.
Phenobarbital levels can be altered by drugs that inhibit or induce CYP enzymes, requiring dose adjustments.
May decrease the effectiveness of hormonal contraceptives, necessitating alternative contraception methods.
Interacts with anticoagulants like warfarin, potentially lowering their anticoagulant effect and increasing thrombotic risk.
May interact with valproic acid leading to altered plasma concentrations and increased toxicity risk.
Combination with antidepressants or antipsychotics can increase CNS depressant effects.
Altered clearance when used with medications that affect renal excretion or liver metabolism (e.g., rifampin, phenytoin, carbamazepine).
Drugs that cause respiratory depression can have additive life-threatening effects.
Interactions with certain antibiotics (e.g., isoniazid) may increase phenobarbital plasma levels.
Phenobarbital may reduce efficacy of drugs metabolized through CYP pathways, such as theophylline and digoxin.
Caution when using with antiretroviral drugs due to potential alterations in drug levels.
Co-administration with other sedative-hypnotic drugs requires careful monitoring.
Interactions with herbal supplements such as St. John’s Wort may alter phenobarbital metabolism.
May interfere with laboratory tests including serum bilirubin and thyroid function tests.

Preparations Of The Drug

Oral Elixir: phenobarbital 20 mg per 5 mL solution for precise dosing especially in pediatric patients.
Oral Tablets available in multiple strengths: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, and 100 mg to allow flexible dosing adjustments.
Injectable formulations (e.g., Sezaby) for intravenous or intramuscular administration in acute settings such as status epilepticus (not detailed in provided data but clinically available).
Combination products with other antiepileptics (less commonly used) for specific clinical protocols.
Tablet formulations suitable for extended use with stable pharmacokinetics.
Liquid formulations designed for ease of administration in children or patients with swallowing difficulties.
Commercially available generics and brand-name preparations to suit cost and access considerations.
Storage recommended at room temperature, protected from moisture, heat, and light to maintain drug stability.
Packaging includes child-resistant caps to prevent accidental ingestion and misuse.
Formulations designed for once or twice daily dosing to improve adherence.
Comes with detailed patient information leaflets for safe use and monitoring of side effects.
Available in multiple countries with regulatory approval for various indications.